Medine.co.uk

Rasagiline 1 Mg Tablets

Document: leaflet MAH GENERIC_PL 35667-0008 change

PACKAGE LEAFLET: INFORMATION FOR THE USER

Rasagiline 1mg TABLETS

Rasagilline

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

-    Keep this leaflet. You may need to read it again.

-    If you have any further questions, ask your doctor or pharmacist.

-    This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.

-    If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

What is in this leaflet:

1.    What Rasagiline is and what it is used for

2.    What do you need to know before you take Rasagiline

3.    How to take Rasagiline

4.    Possible side effects

5.    How to store Rasagiline

6.    Contents of the pack and other information

1.    What Rasagiline is and what it is used for

Rasagiline is used for the treatment of Parkinson’s disease. It can be used together with or without Levodopa (another medicine that is used to treat Parkinson’ s disease).

With Parkinson’s disease, there is a loss of cells that produce dopamine in the brain. Dopamine is a chemical in the brain involved in movement control. Rasagiline helps to increase and sustain levels of dopamine in the brain.

2.    What do you know before you take Rasagiline

Do not take Rasagiline

-    if you are allergic (hypersensitive) to Rasagiline or any of the other ingredients

-    if you have severe liver problems.

Do not take the following medicines while taking Rasagiline:

-    monoamine oxidase (MAO) inhibitors (e.g. for treatment of depression or Parkinson’s disease, or used for any other indication), including medicinal and natural products without prescription e.g. St. John's Wort.

-    pethidine (a strong pain killer).

You must wait at least 14 days after stopping Rasagiline treatment and starting treatment with MAO inhibitors or pethidine.

Warnings and precautions

Talk with your doctor before taking Rasagiline:

-    if you have mild to moderate liver problems

-    You should speak with your doctor about any suspicious skin changes.

Children

Rasagiline is not recommended for use under the age of 18.

Other medicines and Rasagiline

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

Ask your doctor for advice before taking any of the following medicines together with Rasagiline:

-    Certain antidepressants (selective serotonin reuptake inhibitors, selective serotonin-norepinephrine reuptake inhibitors, tricyclic or tetracyclic antidepressants)

-    the antibiotic ciprofloxacin used against infections

-    the cough suppressant dextromethorphan

-    sympathomimetics such as those present in eye drops, nasal and oral decongestants and cold medicine containing ephedrine or pseudoephedrine

The use of Rasagiline together with the antidepressants containing fluoxetine or fluvoxamine should be avoided.

If you are starting treatment with Rasagiline, you should wait at least 5 weeks after stopping fluoxetine treatment.

If you are starting treatment with fluoxetine or fluvoxamine, you should wait at least 14 days after stopping Rasagiline treatment.

Tell your doctor if you or your family/carer notices that you are developing unusual behaviors where you cannot resist the impulse, urges or cravings to carry out certain harmful or detrimental activities to yourself or others. These are called impulse control disorders. In patients taking Rasagiline and/or other medications used to treat Parkinson’s disease, behaviours such as compulsions, obsessive thoughts, addictive gambling, excessive spending, impulsive behaviour and an abnormally high sex drive or an increase in sexual thoughts or feelings have been observed. Your doctor may need to adjust or stop your dose.

Rasagiline with food and drink and alcohol

Rasagiline may be taken with or without food.

Pregnancy and breast-feeding and fertility

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby ask your doctor or pharmacist for advice before taking this medicine.

Driving and using machines

No studies on the effects on the ability to drive and use machines have been performed.

Ask your doctor for advice prior to driving or using machines.

3.    How to take Rasagiline

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

The recommended dose of Rasagiline is 1 tablet of 1 mg taken by mouth once daily. Rasagiline may be taken with or without food.

If you take more Rasagiline than you should

If you think that you may have taken too many Rasagiline tablets, contact your doctor or pharmacist immediately.

Take the Rasagiline carton with you to show the doctor or pharmacist.

If you forget to take Rasagiline

Do not take a double dose to make up for a forgotten dose. Take the next dose normally, when it is time to take it.

If you stop taking Rasagiline

Do not stop taking Rasagiline without first talking to your doctor.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

4.    Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects have been reported in placebo controlled clinical trials:

The frequency of possible side effects listed below is defined using the following convention:

I Very common (affects more than 1 user in 10)

Common (affects 1 to 10 users in 100)

I Uncommon (affects 1 to 10 users in 1,000)

I Rare (affects 1 to 10 users in 10,000)

Very rare (affects less than 1 user in 10,000)

I Not known (frequency cannot be estimated from the available data)

Very common

-    abnormal movements (dyskinesia)

-    headache

Common:

-    abdominal pain

-    fall

-    allergy

-    fever

-    flu (influenza)

-    general feeling of being unwell (malaise)

-    neck pain

-    chest pain (angina pectoris)

-    low blood pressure when rising to a standing position with symptoms like dizziness/light-headedness

(orthostatic hypotension)

-    decreased appetite

-    constipation

-    dry mouth

-    nausea and vomiting

-    flatulence

-    abnormal results of blood tests (leucopenia)

-    joint pain (arthralgia)

-    musculoskeletal pain

-    joint inflammation (arthritis)

-    numbness and muscle weakness of the hand (carpal tunnel syndrome)

-    decreased weight

-    abnormal dreams

-    difficulty in muscular coordination (balance disorder)

-    depression

-    dizziness (vertigo)

-    prolonged muscle contractions (dystonia)

-    runny nose (rhinitis)

-    irritation of the skin (dermatitis)

-    rash

-    bloodshot eyes (conjunctivitis)

-    urinary urgency

Uncommon:

-    stroke (cerebrovascular accident)

-    heart attack (myocardial infarction)

-    blistering rash (vesiculobullous rash)

In addition, skin cancer was reported in around 1% of patients in the placebo controlled clinical trials. Nevertheless, scientific evidence suggests that Parkinson’s disease, and not any medicine in particular, is associated with a higher risk of skin cancer (not exclusively melanoma). You should speak with your doctor about any suspicious skin changes.

Parkinson's disease is associated with symptoms of hallucinations and confusion.

In post marketing experience these symptoms have also been observed in Parkinson's disease patients treated with Rasagiline.

There have been cases of patients who, while taking one or more medications for the treatment of Parkinson’s disease, were unable to resist the impulse, drive or temptation to perform an action that could be harmful to themselves or others. These are called impulse control disorders. In patients taking Rasagiline and/or other medications used to treat Parkinson’s disease, the following have been observed:

-    Obsessive thoughts or impulsive behaviour.

-    Strong impulse to gamble excessively despite serious personal or family consequences.

-    Altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive.

-    Uncontrollable excessive shopping or spending.

Tell your doctor if you experience any of these behaviours; they will discuss ways of managing or reducing the symptoms.

Reporting of side effects

If you get any side effects, talk your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.

5.    HOW TO STORE Rasagiline

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton or blister. The expiry date refers to the last day of that month.

Store bellows 30°C.

Do not use this medicine if you notice visible signs of deterioration.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

6.    CONTENT OF THE PACK AND OTHER INFORMATION

What Rasagiline contains

-    The active substance is Rasagiline. Each tablet contains 1 mg Rasagiline (tatratate).

-    The other ingredients microcrystalline cellulose, colloidal silicon dioxide, sodium starch glycolate (potato) and sodium stearyl fumarate

What Rasagiline looks like and contents of the pack

Rasagiline tablets are presented as white round and biconvex tablets. The tablets are available in blister packs of 30 tablets.

Marketing Authorization Holder and Manufacturer

Marketing Authorization Holder:

Farmalider, S.A Aragoneses, 15 28108 Alcobendas. Madrid Spain

Manufacturer:

Farmalider, S.A Aragoneses, 15 28108 Alcobendas. Madrid Spain

or

Toll Manufacturing Services, S.L.

Aragoneses, 2

28108 Alcobendas.Madrid

Spain

This leaflet was last revised in 05/2016